Red blood cell storage age – what we know from clinical trials

Kenneth E. Remy,P. Spinella

DOI: https://doi.org/10.1080/17474086.2016.1243051

2016-10-08

Expert Review of Hematology

Abstract:Red blood cell (RBC) transfusion has become one of the most commonly utilized life-saving therapies in medicine with approximately 12–16 million units transfused in the US per year [1,2]. Since storage solutions were developed 100 years ago, they have been modified to allow for increased storage duration, primarily to increase availability, especially in remote areas, such as during combat operations [3]. Currently in the US and Europe, RBCs can be stored up to 42–56 days based upon at least 75% of radiochromium-labeled cells remaining in the circulation at 24 h after infusion and hemolysis less than 1% [4,5]. As RBCs are stored over time, the metabolic and biochemical changes that occur have been coined ‘the storage lesion.’ To further improve the availability of RBCs, it is standard for blood distributors to transfer RBCs that are close to expiration at community hospitals to medical centers where utilization rates are higher, and for hospital blood banks to issue the ‘first-in, first-out’ inventory to reduce RBC outdating and waste [2,6]. A consequence of these policies focused on inventory management is that patients with increased severity of illness are transfused RBCs of increased storage duration compared to less acutely ill patients. It is important to recognize that as storage duration for RBC units has increased for logistical purposes, there has not been a commensurate evaluation of clinical efficacy or safety. As a result of the preferential allocation of older RBCs to sicker patients, there has been concern regarding the quality of RBCs after prolonged storage related to both efficacy and safety. This has led to a significant amount of research into the clinical relevance of the storage lesion with laboratory, preclinical, and clinical studies [4,7–9]. The results of these studies suggested biologic plausibility that the RBC storage lesion was potentially able to affect outcomes, especially in critically ill populations. These studies though are limited due to potential bias and higher-quality studies were needed to more accurately determine if RBC storage age affects outcomes. Consequently, a few randomized controlled trials (RCTs) have been completed, and a few are still underway. Dissecting out what each of these studies may mean for patients who are transfused RBCs based upon the population studied and their design is controversial. 2. ‘Storage lesion’